TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
BRIDGEWATER, N.J., Aug. 01, 2017 -- Valeritas Holdings, Inc. (NASDAQ:VLRX) announced today that John Timberlake, President and Chief Executive Officer, and Erick Lucera, Chief Financial Officer, are scheduled to present at the Wedbush PacGrow Healthcare Conference. The Company will also participate in the Drug Delivery Technologies Panel moderated in part by Tao Levy, Managing Director Medical Devices Equity Research.
| Event: | Wedbush Drug Delivery Technologies Panel | |
| Date: | Tuesday, August 15, 2017 | |
| Time: | 11:30 a.m. EDT | |
| Location: | New York, NY | |
| Event: | Wedbush PacGrow Healthcare Conference Company Presentation | |
| Date: | Wednesday, August 16, 2017 | |
| Time: | 9:10 a.m. EDT | |
| Location: | New York, NY | |
An audio webcast of the Company’s presentation will be available by visiting the investor relations section of the Valeritas website at www.valeritas.com. Replays of the presentation will be available for 90 days.
About Valeritas, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.
Investor Contact: Robert E. Flamm, Ph.D. / Brian Johnston The Ruth Group 646-536-7017 / 7028 [email protected] Or The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 [email protected] Media Contact: Kirsten Thomas / Cari Randall The Ruth Group 508-280-6592 / 646-536-7002 [email protected]
